Expand CADL Menu
CADL MENU

CADL Latest Press Releases

-- July 1, 2026 --

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 30, 2026 --

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors Globe Newswire 8:05 AM

-- June 25, 2026 --

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer Globe Newswire 8:05 AM

-- June 2, 2026 --

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Globe Newswire 8:05 AM

-- June 1, 2026 --

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- May 15, 2026 --

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting Globe Newswire 4:05 PM

-- May 14, 2026 --

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights Globe Newswire 8:05 AM

-- May 13, 2026 --

Candel Therapeutics to Present at Upcoming Investor Conferences Globe Newswire 8:05 AM

-- May 4, 2026 --

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting Globe Newswire 8:05 AM

-- May 1, 2026 --

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- April 29, 2026 --

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer Globe Newswire 8:05 AM

-- April 2, 2026 --

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- March 17, 2026 --

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors Globe Newswire 8:05 AM

-- March 12, 2026 --

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights Globe Newswire 8:05 AM

-- March 9, 2026 --

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting Globe Newswire 8:05 AM

-- March 2, 2026 --

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- February 24, 2026 --

Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston Globe Newswire 8:05 AM

-- February 19, 2026 --

Candel Therapeutics Announces Pricing of Public Offering Globe Newswire 9:40 PM
Candel Therapeutics Announces Proposed $100 Million Public Offering Globe Newswire 4:05 PM
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Globe Newswire 4:01 PM

-- February 11, 2026 --

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit Globe Newswire 8:05 AM
Market Data Delayed 15 Minutes